OCR 5199

Yale researchers have identified that the acute inflammatory response to biomaterials can be limited by inhibition of inflammasome-related pathways.

OCR 52543105

OCR3105/5254 pertains to the creation of a simple tool kit for the efficient site specific, phosphorylation signal-independent, introduction of phosphoserine into proteins in vitro and in vivo using a novel vector compatible with complementary bacterial strains and mammalian tissue culture.

OCR 57674445

Mice that overexpress TGF-β have identified several novel targets (including β1 integrin) for therapeutic interventions in fibrotic lung diseases. Semaphorin 7A inhibition is also effective as a therapeutic treatment for fibrotic disease.

OCR 6320
OCR6320 is a safe and efficacious novel vaccine candidate for the treatment of Leptospira infections.
OCR 6185

Yale researchers created an inactivated version of the thyphoid toxin, which can serve as the basis for the development of novel second-generation vaccines to treat typhoid fever.

OCR 5339

OCR 5339 is a novel serum-based biomarker assay that determines disease severity and provides a prediction of the progression of scleroderma.

OCR 5475
Yale researchers have identified a new use for YKL-40 – as a protein-based biomarker for renal disease and a predictor of kidney allograft success.
OCR 1642

GFB-204 is a novel compound that binds PDGF and VEGF and prevents binding to their respective receptors, and subsequently suppresses downstream signaling pathways.